EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment

Liza M Y Gelissen, Eva M M Strijbis, Bob W van Oosten, Brigit A de Jong, Agnes I Veldkamp, Theo Rispens, Joep Killestein, Zoé L E van Kempen

Multiple Sclerosis and Related Disorders · 2026-05 · 109 · 107147

DOI: 10.1016/j.msard.2026.107147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis and Related Disorders, 2026-05. Verfasst von Liza M Y Gelissen und 7 weiteren Autor:innen. Beteiligte Einrichtung: MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Am…. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals, Immunologic Factors, Patient Satisfaction. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabBiosimilar PharmaceuticalsImmunologic FactorsPatient SatisfactionMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisHumansFemaleAdultMaleMiddle AgedDrug SubstitutionSurveys and Questionnaires

Stichwörter der Autor:innen

BiosimilarJC virusMultiple sclerosisNatalizumabReal-world cohort

Substanzen

NatalizumabBiosimilar PharmaceuticalsImmunologic Factors

Autor:innen und Institutionen

  • MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands. Electronic address: l.m.y.gelissen@amsterdam…
  • MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands.
  • Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands.
  • Research & Lab Services Dept, Sanquin Blood Supply, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherla…

Zitieren

APA

Gelissen, L. M. Y., Strijbis, E. M. M., van Oosten, B. W., de Jong, B. A., Veldkamp, A. I., Rispens, T., Killestein, J., & van Kempen, Z. L. E. (2026). Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment. Multiple Sclerosis and Related Disorders, 109, 107147. https://doi.org/10.1016/j.msard.2026.107147

Vancouver

Gelissen LMY, Strijbis EMM, van Oosten BW, de Jong BA, Veldkamp AI, Rispens T, et al. Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment. Multiple Sclerosis and Related Disorders. 2026;109:107147. doi:10.1016/j.msard.2026.107147

BibTeX
@article{Gelissen2026,
  author = {Gelissen, Liza M Y and Strijbis, Eva M M and van Oosten, Bob W and de Jong, Brigit A and Veldkamp, Agnes I and Rispens, Theo and Killestein, Joep and van Kempen, Zoé L E},
  title = {Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment},
  journal = {Multiple Sclerosis and Related Disorders},
  year = {2026},
  volume = {109},
  pages = {107147},
  doi = {10.1016/j.msard.2026.107147}
}
Kostenlos starten →